Edition:
India

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

2.19USD
10:01pm IST
Change (% chg)

$0.07 (+3.30%)
Prev Close
$2.12
Open
$2.10
Day's High
$2.21
Day's Low
$2.09
Volume
166,822
Avg. Vol
206,449
52-wk High
$9.69
52-wk Low
$2.06

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $396.17
Shares Outstanding(Mil.): 51.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines

* TETRAPHASE PHARMACEUTICALS ENTERS INTO EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH EVEREST MEDICINES FOR ERAVACYCLINE IN CHINA

21 Feb 2018

Tetraphase's antibiotic fails late-stage study, shares plummet

Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares plunging more than 60 percent in after-market trading.

14 Feb 2018

BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI

* TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE3 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN COMPLICATED URINARY TRACT INFECTIONS (CUTI)

14 Feb 2018

BRIEF-Tetraphase Pharmaceuticals Files For Mixed Shelf Of Up To $150 Mln

* FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2n8xDCf) Further company coverage:

26 Jan 2018

BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections

* TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

03 Jan 2018

BRIEF-Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14

* MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING Source text: (http://bit.ly/2kt52WQ) Further company coverage:

21 Dec 2017

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements

02 Nov 2017

BRIEF-Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga

* Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing

21 Oct 2017

BRIEF-TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO

* TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER

16 Oct 2017

BRIEF-Tetraphase Pharmaceuticals presents clinical data from oral eravacycline development program at IDWEEK 2017​

* Tetraphase Pharmaceuticals - ‍phase 2 trial in patients with complicated urinary tract infections expected to begin in h1 2018​

04 Oct 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $130.97 +1.06
Pfizer Inc. (PFE.N) $36.07 +0.33
Merck & Co., Inc. (MRK.N) $54.74 +0.17
AstraZeneca plc (AZN.L) 4,753.00 -19.00

Earnings vs. Estimates